This contrast reflects not only the efficacy of trastuzumab in the treatment of HER2-positive BC but also the importance of good tolerability and a manageable safety profile, which are essential to ensure treatment adherence and thus improve survival outcomes in this patient population. The gene discussed is ERBB2; the disease is breast cancer.